N4-Hydroxycytidine is a cytidine analog being investigated to treat COVID-19. N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.
- Mechanism
- Curator reviewed · 3 references
N4-hydroxycytidine is phosphorylated in tissue to the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations, known as viral error catastrophe. A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.
- Primary indication
- N4-hydroxycytidine and its prodrug EIDD-2801 is being studied for its activity against a number of viral infections including influenza, MERS-CoV, and SARS-CoV-2.Curator reviewed
- Formula / weight
- C9H13N3O6 · 259.218 g/mol (avg)
- Also known as
- 4-N-Hydroxycytidine · beta-D-N-4-Hydroxycytidine · Beta-D-N4-hydroxycytidine · N(4)-Hydroxycytidine · NHC
- Code names
- EIDD-1931
Resolves to
XCUAIINAJCDIPM-XVFCMESISA-NSMILESOC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(NO)=NC1=OWhat you can answer from here — as of August 25, 2026
Which drugs share a target with N4-Hydroxycytidine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account